Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | cytochrome P450 reductase | 0.0079 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0079 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0079 | 1 | 1 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0079 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0079 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0079 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0079 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0079 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0079 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0079 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0079 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0079 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0039 | 0 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0079 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0079 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0039 | 0 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.007 | 0.7743 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.004 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0079 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0079 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0049 | 0.2407 | 0.2407 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0079 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0079 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0049 | 0.2407 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0079 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0079 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.007 | 0.7743 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0079 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.